| 查看: 877 | 回复: 2 | |||||
1949stone荣誉版主 (知名作家)
海纳百川
|
[交流]
Guidance for Industry-Electronic Source Data in Clinical Investigations 已有2人参与
|
|
I. INTRODUCTION This guidance provides recommendations to sponsors, Contract Research Organizations (CROs), clinical investigators, and others involved in the capture, review, and retention of electronic source data in FDA-regulated clinical investigations.2 In an effort to streamline and modernize clinical investigations this guidance promotes capturing source data in electronic form, and it is intended to assist in ensuring the reliability, quality, integrity, and traceability of data from electronic source to electronic regulatory submission. This guidance addresses source data in clinical investigations used to fill the predefined fields in an electronic case report form (eCRF), according to the protocol. The guidance discusses the following topics related to electronic source data: Identification and specification of authorized source data originators Creation of data element identifiers to facilitate examination of the audit trail by sponsors, FDA, and other authorized parties Ways to capture source data into the eCRF using either manual or electronic methods Clinical investigator(s) responsibilities with respect to reviewing and retaining electronic data Use and description of computerized systems in clinical investigations This guidance is intended to be used together with the FDA guidance for industry on Computerized Systems Used in Clinical Investigations (the computerized systems guidance),and FDA regulation on Electronic Records and Electronic Signatures.4 Electronic structures and standards related to electronic submissions are out of scope for this guidance. FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.[ Last edited by 1949stone on 2014-1-23 at 08:26 ] |
回复此楼» 本帖附件资源列表
-
欢迎监督和反馈：小木虫仅提供交流平台，不对该内容负责。
本内容由用户自主发布，如果其内容涉及到知识产权问题，其责任在于用户本人，如对版权有异议，请联系邮箱：xiaomuchong@tal.com - 附件 1 : UCM328691.pdf
- 附件 2 : 2013-22645.pdf
2014-01-23 08:23:28, 190.31 K
2014-01-23 08:26:11, 187.19 K
» 收录本帖的淘帖专辑推荐
 颛顼药学 | 考研资料 |
» 猜你喜欢
211高校2026年入学博士名额
已经有15人回复
-
211高校2026年入学博士名额
已经有16人回复
-
药物学论文润色/翻译怎么收费?
已经有257人回复
-
海勃原辅料助力银屑病一线外用制剂开发
已经有0人回复
-
二乙烯基砜的合成路径
已经有4人回复
-
求一株[b]敲除MTAP(human)的HCT-116(人结肠癌细胞)/b]细胞
已经有0人回复
-
求助！求美国食品化学药典内容：FCC13【低聚果糖专论】
已经有0人回复
-
【2027博士申请】纳米药物递送方向
已经有5人回复
-
消耗微量API，便可预测早期研发阶段的HME工艺可行性
已经有0人回复
-
反应液中苯酐除去
已经有1人回复
 |
2楼2014-01-23 09:10:41
|
|
3楼2014-01-24 11:06:37
